ArticleAdvances in therapy2026
Predicting Long-Term Weight Loss Using Self-Reported, Digitally Collected, Real-World Data After Initiation of Semaglutide for Overweight or Obesity.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating Precision Nutrition with GLP-1 Receptor Agonist Therapy: Mechanisms, Clinical Outcomes, and Pharmacoeconomic Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- From explainability to clinical actionability: translating artificial intelligence models into decision support for endocrine disease management.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe hypothesised that an exposure-response weight predictor algorithm developed from randomised controlled trial data can predict long-term individual body weight changes in both men and women in response to subcutaneous semaglutide treatment for weight management using self-reported, real-world data, collected through a digital patient support program (PSP).
methodsAn exposure-response body weight prediction model developed from clinical trials with semaglutide in people with overweight or obesity was applied to a real-world dataset from patients prescribed semaglutide (0.25-2.4 mg) by their treating healthcare provider (HCP) and enrolled into an app-based PSP. Model variables were baseline sex and body weight, and self-reported dosing and body weight during semaglutide treatment. Predictions were assessed in two scenarios. In the first scenario, body weight at 26 ± 4 weeks was predicted from baseline data with model updates at weeks 4, 8, and 16. In the second scenario, body weight at 52 ± 4 weeks was predicted from baseline data with updates at weeks 8, 16, and 28. Model bias was calculated as the difference between predicted and self-reported body weight, while precision for predicting categorical weight loss (≥ 10%, ≥ 15%, ≥ 20%) was assessed using area under the curve (AUC).
resultsThe study included 1797 WegovyCare® app users, predominantly women (81%), with a mean (SD) age of 48.0 (11.8) years. Mean (SD) self-reported body weight in the entire population was 105 (19.5) kg at baseline. In the half-year scenario, users lost an average of 15% (15.6 kg). Model bias was low (0.7-1.4 kg) and precision for predicting categorical weight loss was high (AUC 0.74-0.95). In the full-year scenario, average weight decreased by 21% (22.0 kg) with similarly low bias (-0.6 to 0.6 kg) and high prediction precision for categorical weight loss (AUC 0.75-0.92).
conclusionThis study successfully applied an exposure-response weight predictor algorithm to self-reported data collected from users in the real world. Integrating weight predictors into digital PSPs may be valuable for both patients and HCPs in managing weight loss and setting or monitoring treatment targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.